NCT00212784View on ClinicalTrials.gov

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,225

Participants

Timeline

Start Date

September 4, 2003

Primary Completion Date

March 15, 2006

Study Completion Date

March 15, 2006

Conditions

SchizophreniaSchizoaffective Disorder

Interventions

DRUG

asenapine

Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.

DRUG

olanzapine

Oral capsules (5 mg or placebo); 1 to 2 tablets twice daily

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) | Biotech Hunter | Biotech Hunter